for Health Care Providers
Back to Summary of Current Recommendations
| PARAMETER | RECOMMENDATION |
|---|---|
| In stable underlying cardiac disease, reduce ribavirin by 200 mg/day for ≥2 g/dL drop in Hb over a four-wk period. If the Hb level is <12 g/dL after four wk of dose reduction, discontinue ribavirin until resolution and reevaluation. | |
| Hemoglobin (Hb) | |
| <11.0 but >10 g/dL | No change in ribavirin dose if patient has minimal symptoms |
| In a symptomatic patient, consider ribavirin dose reduction by 200 mg/day and/or starting an erythropoietic growth factor | |
| <10.0 but >8.5 g/dL | Decrease ribavirin by 200 mg/day and/or consider starting an erythropoietic growth factor |
| Recheck Hb levels at least every 2 wk or more frequently if indicated | |
| <8.5 g/dL | Discontinue until resolution |
